Wednesday, June 24, 2020, 5:00 PM – 6:00 PM ET

Chronic Lymphocytic Leukemia and Follicular Lymphoma

Faculty

Jeff Sharman, MD
Willamette Valley Cancer Institute and
Research Center
Medical Director of Hematology Research
US Oncology
Eugene, Oregon


Julie M Vose, MD, MBA
Neumann M and Mildred
E Harris Professor
Chief, Division of Hematology/Oncology
Nebraska Medical Center
Omaha, Nebraska

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Not an official event of the ASCO20 Virtual Program. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

Topics for Discussion

Chronic Lymphocytic Leukemia (CLL)

  • Optimizing the selection and sequencing of therapy for patients with newly diagnosed CLL requiring treatment
  • Phase III trials evaluating ibrutinib-based therapy in younger and older patients with treatment-naïve CLL
  • Key data sets leading to the FDA approval of acalabrutinib (ELEVATE-TN, ASCEND trials) for newly diagnosed and previously treated CLL
  • FDA approval and current role of venetoclax-based regimens for the treatment of newly diagnosed and relapsed/refractory CLL
  • Integration of available PI3 kinase inhibitors into current CLL treatment algorithms
  • Monitoring for and management of toxicities associated with agents and regimens commonly employed in CLL treatment
  • Ongoing evaluation of novel combination approaches for newly diagnosed CLL

Follicular Lymphoma (FL)

  • Obinutuzumab-based induction and maintenance therapy for previously untreated FL
  • Results of the Phase III trials evaluating lenalidomide/rituximab (R2) in newly diagnosed (RELEVANCE) and relapsed/refractory FL (AUGMENT); FDA approval of R2 for previously treated FL
  • Available research data with PI3 kinase inhibitors and their current role in the treatment of FL
  • Novel and emerging agents and strategies in FL management (eg, tazemetostat, CAR T-cell therapy)

Target Audience

This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL).

Learning Objectives

  • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed or relapsed/refractory (R/R) CLL, considering clinical presentation and biomarker profile.
  • Evaluate existing and emerging clinical research data to formulate therapeutic recommendations for patients with newly diagnosed or R/R FL.
  • Compare and contrast the mechanisms of action, efficacy and safety of approved PI3 kinase inhibitors in the treatment of R/R CLL and FL.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for CLL and FL to support quality of life and continuation of treatment.
  • Assess the ongoing clinical trials evaluating other novel investigational approaches for CLL and FL, and obtain consent from appropriate patients for study participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr SharmanAdvisory Committee, Consulting Agreements and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc. Dr VoseConsulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Allogene Therapeutics, Celgene Corporation, Epizyme, Legend Biotech, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, Vaniam Group, Verastem Inc, Wugen; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Celgene Corporation, Incyte Corporation, Kite, A Gilead Company, Novartis, Seattle Genetics.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

RTP CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Kite, A Gilead Company, Seattle Genetics and Verastem Inc.